DBV Technologies (DBVT) Expected to Announce Quarterly Earnings on Friday

DBV Technologies (NASDAQ:DBVT) will likely be announcing its Q4 2025 results before the market opens on Friday, April 10th. Analysts expect the company to announce earnings of ($0.1564) per share and revenue of $1.0890 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, April 2, 2026 at 7:00 AM ET.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings results on Saturday, February 14th. The company reported ($1.15) EPS for the quarter. The firm had revenue of $0.65 million for the quarter. DBV Technologies had a negative net margin of 2,606.83% and a negative return on equity of 189.17%. On average, analysts expect DBV Technologies to post $-7 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

DBV Technologies Price Performance

DBVT opened at $21.51 on Thursday. The company has a fifty day moving average price of $21.25 and a 200-day moving average price of $17.89. The firm has a market capitalization of $1.20 billion, a P/E ratio of -4.12 and a beta of -0.94. DBV Technologies has a one year low of $6.69 and a one year high of $26.18.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on DBVT shares. Citizens Jmp boosted their price target on shares of DBV Technologies from $45.00 to $47.00 and gave the company a “market outperform” rating in a research report on Friday, March 27th. Guggenheim restated a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a research report on Friday, March 27th. Cantor Fitzgerald set a $48.00 price objective on shares of DBV Technologies in a report on Wednesday, December 17th. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. Finally, Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $38.65.

Institutional Trading of DBV Technologies

A number of hedge funds have recently made changes to their positions in DBVT. Artisan Partners Limited Partnership lifted its stake in DBV Technologies by 6,273.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock worth $63,435,000 after purchasing an additional 3,257,135 shares during the last quarter. Vivo Capital LLC lifted its stake in DBV Technologies by 133.4% in the fourth quarter. Vivo Capital LLC now owns 2,461,626 shares of the company’s stock worth $47,189,000 after purchasing an additional 1,407,120 shares during the last quarter. Siren L.L.C. bought a new stake in DBV Technologies in the fourth quarter worth $35,606,000. Adage Capital Partners GP L.L.C. bought a new stake in DBV Technologies in the second quarter worth $9,659,000. Finally, MPM Bioimpact LLC bought a new stake in DBV Technologies in the second quarter worth $9,649,000. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.